Forum for Science, Industry and Business
  • Sponsored by:
  • Siemens
  • Siemens
  • Siemens
Search our Site:

Topic (optional):

 

Home Reports Life Sciences Content

Genomics and world peace

next article
10.09.2002

 


Developing countries stand to profit most from advances in genome science, write Samuel Broder, Stephen Hoffman and Peter Hotez in this month’s issue of EMBO reports (EMBO reports September, 2002 pp 806–812). They claim that biotechnology coupled with genomics might emerge as the key technology in the 21st century for improving global health and probably even avoiding major political conflicts and wars.


The authors warn that we must no longer view the diseases of the developing world in purely medical or public health contexts. Infectious diseases could pose a major risk to the economic survival of many developing nations. Even more striking, recent data suggest that some of these diseases may have wider implications for geopolitical stability or the probability that a nation will experience armed conflict. "If it is possible to transfer weapon technology to the developing world it should be possible to transfer innovative countertechnologies to these countries. We believe that genomics could be such a countertechnology," says Samuel Broder.

The progress resulting from genomic research is significant. It has already advanced our knowledge of infectious diseases. The complete genomic sequences of many pathogens responsible for morbidity and mortality in the developing world are now established. The new tools in comparative genomics, computational biology, and informatics have already yielded promising results in studying invertebrate parasites that cause tropical diseases. When combined with the sequence of the human genome, and the sequence of some of the vectors of disease, like the Anopheles mosquitoes that transmit malaria parasites, they offer remarkable opportunities for reducing the negative impact of these diseases.

However, the authors point out that the applications of this research might only benefit patients in the First World, since there has been little or no commercial interest in developing treatments against the tropical diseases that occur among the world’s poorest people. The authors illustrate this with several diseases such as malaria, hookworm and AIDS. "To achieve greater impact for the developing countries it will be necessary to combine the efforts made by some not-for-profit organisations and private funds to support research for the developing world and to link genomic research with vaccine research and other technologies." says Samuel Broder. "It will also be necessary to transfer these new technologies to developing countries and to give these countries access to necessary information, such as gene data bases."

Ellen Peerenboom | Source: EurekAlert!
Further information: www.embo.org/press/reports/september.html

next article

More articles from Life Sciences:

nachricht Hope for Alzheimer’s Patients?
04.12.2008 | Angewandte Chemie International Edition

nachricht New "Control Knobs" for Stem Cells Identified
04.12.2008 | Tufts University

B2B Search

Product / Service
Company / Organisation

Latest News

New solutions enhancing road safety developed in Finland

04.12.2008 | Transportation and Logistics

Why is the Earth’s mantle conductive?

04.12.2008 | Earth Sciences

ESA satellites flying in formation

04.12.2008 | Physics and Astronomy

Event News

Dublin to host Europe’s largest interdisciplinary science conference in 2012

28.11.2008 | Event News

ECREA Barcelona 2008

28.11.2008 | Event News

The Automobile – The Transition from Energy Guzzler to Power Supplier

20.11.2008 | Event News